Termination of the enterprise mix with Next Sight Medical Products, Inc.

Termination of the business combination with
Second Sight Healthcare Goods, Inc.

Paris, France, April 3, 2021 – Contemplating the personal placement not long ago announced and closed by Next Sight Professional medical Items, Inc. (“2nd Sight”) was not only explicitly prohibited less than the conditions of the memorandum of comprehension (“MOU”) entered into by the organizations on January 5, 2021¹ but also harmful to Pixium Vision’s passions, the corporation has made available Second Sight to renegotiate the MOU in purchase to allow for the pursuit of the small business blend though preserving the contractual equilibrium and the interests of Pixium Eyesight and its shareholders. Pixium Eyesight regrets that Next Sight under no circumstances responded to the proposals it produced in fantastic faith nor shown any willingness to access these kinds of agreement.

Next this delaying frame of mind and refusal to enter into discussions, 2nd Sight notified Pixium Eyesight on Friday its conclusion to unilaterally terminate the MOU, notwithstanding that the MOU does not offer Next Sight with this proper.

Pixium Eyesight acknowledges the unilateral and wrongful termination by Next Sight of the MOU and the contemplated small business mix. For that reason, Pixium Eyesight will think about all measures obtainable (which includes any authorized proceedings, in certain with the appropriate stock trade authorities) to maintain its rights and get hold of payment for its total damages.

This sort of termination does not compromise the company’s goals in the context of the new compelling final results with Prima System announced by Pixium Eyesight on March 30, 2021², an critical phase forward validating the Prima Program as a cure for dry age-associated macular degeneration.

Lloyd Diamond, CEO of Pixium Eyesight commented: “Though we are naturally unhappy in the position staying taken by Next Sight and that this organization combination has not proceeded, Pixium Eyesight is in a sturdy place each fiscally and clinically, with a world-class Exploration & Development workforce and core know-how in eyesight neuromodulation and a solid patent portfolio. We are continuing our changeover from a research firm to a commercially oriented organization with the new initiation of our PRIMAvera pivotal demo of the Prima Process. Our ambition is to be the first enterprise in the planet to carry a retinal implant resolution to the millions of people today throughout the world struggling with Dry-AMD and extend this to other retinal illnesses. This is supported by the recently noted facts exhibiting people could simultaneously use prosthetic central vision created with the Prima Procedure and their remaining peripheral eyesight. We are very well positioned to continue on the enhancement of this interesting bionic eyesight system and deliver it to marketplace to boost patients’ high quality of daily life”.

Tale carries on

Pixium Eyesight is assured in its capability to current to its shareholders, at the once-a-year standard assembly, alternative funding solutions in buy to empower the enterprise to go after the advancement of its activity. The business will examine in the meantime any chance to obtain the US marketplaces, one of the most important targets pursued by Pixium Eyesight under the business enterprise combination with Next Sight, which is in the best curiosity of clients and its shareholders.

Contacts

Pixium Eyesight is developing a world of bionic vision for those people who have missing their sight, enabling them to get back visible notion and better autonomy. Pixium Vision’s bionic vision techniques are affiliated with a surgical intervention and a rehabilitation period. Prima Method sub-retinal miniature photovoltaic wi-fi implant is in medical tests for sufferers who have dropped their sight because of to outer retinal degeneration, initially for atrophic dry age-associated macular degeneration (dry AMD). Pixium Eyesight collaborates intently with academic and investigate companions, which include some of the most prestigious eyesight investigate establishments in the entire world, these kinds of as: Stanford University in California, Institut de la Eyesight in Paris, Moorfields Eye Medical center in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University healthcare facility in Bonn, and UPMC in Pittsburgh, PA. The enterprise is EN ISO 13485 accredited and qualifies as “Entreprise Innovante” by Bpifrance.

For more facts: http://www.pixium-vision.com/fr

Observe us on @PixiumVision www.fb.com/pixiumvision

www.linkedin.com/enterprise/pixium-vision

¹ Cf. press release issued by Pixium Vision on March 24, 2021

² Cf. push release issued by Pixium Eyesight on March 30, 2021

Attachment